{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:46:17Z","timestamp":1776285977087,"version":"3.50.1"},"reference-count":121,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Epithelial ovarian cancer (EOC) is the deadliest gynaecological malignancy and the eighth most prevalent cancer in women, with an abysmal mortality rate of two million worldwide. The existence of multiple overlapping symptoms with other gastrointestinal, genitourinary, and gynaecological maladies often leads to late-stage diagnosis and extensive extra-ovarian metastasis. Due to the absence of any clear early-stage symptoms, current tools only aid in the diagnosis of advanced-stage patients, wherein the 5-year survival plummets further to less than 30%. Therefore, there is a dire need for the identification of novel approaches that not only allow early diagnosis of the disease but also have a greater prognostic value. Toward this, biomarkers provide a gamut of powerful and dynamic tools to allow the identification of a spectrum of different malignancies. Both serum cancer antigen 125 (CA-125) and human epididymis 4 (HE4) are currently being used in clinics not only for EOC but also peritoneal and GI tract cancers. Screening of multiple biomarkers is gradually emerging as a beneficial strategy for early-stage diagnosis, proving instrumental in administration of first-line chemotherapy. These novel biomarkers seem to exhibit an enhanced potential as a diagnostic tool. This review summarizes existing knowledge of the ever-growing field of biomarker identification along with potential future ones, especially for ovarian cancer.<\/jats:p>","DOI":"10.3390\/diagnostics13040713","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T03:09:32Z","timestamp":1676344172000},"page":"713","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics"],"prefix":"10.3390","volume":"13","author":[{"given":"Sourav","family":"Chakraborty","sequence":"first","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priti S.","family":"Shenoy","sequence":"additional","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megha","family":"Mehrotra","sequence":"additional","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7898-6074","authenticated-orcid":false,"given":"Pratham","family":"Phadte","sequence":"additional","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prerna","family":"Singh","sequence":"additional","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3509-4794","authenticated-orcid":false,"given":"Bharat","family":"Rekhi","sequence":"additional","affiliation":[{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"},{"name":"Tata Memorial Hospital, Dr. E Borges Road, Parel, Mumbai 400012, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritha","family":"Ray","sequence":"additional","affiliation":[{"name":"Imaging Cell Signaling and Therapeutics Lab, Advanced Centre for Training Research and Education in Cancer, Navi Mumbai 410210, India"},{"name":"Homi Bhabha National Institute, BARC Training School Complex, Anushaktinagar, Mumbai 400094, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.amepre.2015.09.023","article-title":"A systematic review of symptoms for the diagnosis of ovarian cancer","volume":"50","author":"Ebell","year":"2016","journal-title":"Am. J. Prev. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/ALN.0b013e3181d47604","article-title":"Statistical evaluation of a biomarker","volume":"112","author":"Ray","year":"2010","journal-title":"J. Am. Soc. Anesthesiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1021\/pr0501259","article-title":"So, you want to look for biomarkers (introduction to the special biomarkers issue)","volume":"4","author":"LaBaer","year":"2005","journal-title":"J. Proteome Res."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ueland, F.R. (2017). A perspective on ovarian cancer biomarkers: Past, present and yet-to-come. Diagnostics, 7.","DOI":"10.3390\/diagnostics7010014"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: New opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trac.2018.08.017","article-title":"Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches","volume":"108","author":"Razmi","year":"2018","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1172\/JCI110380","article-title":"Reactivity of a monoclonal antibody with human ovarian carcinoma","volume":"68","author":"Bast","year":"1981","journal-title":"J. Clin. Investig."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1111\/jog.14427","article-title":"Serum CA19-9, CA-125 and CEA as tumor markers for mucinous ovarian tumors","volume":"46","author":"Lekskul","year":"2020","journal-title":"J. Obstet. Gynaecol. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"101713","DOI":"10.1016\/j.jogoh.2020.101713","article-title":"Comparison of HE 4, CA 125, ROMA score and ultrasound score in the differential diagnosis of ovarian masses","volume":"49","author":"Aslan","year":"2020","journal-title":"J. Gynecol. Obstet. Hum. Reprod."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/ijc.31164","article-title":"Ovarian cancer early detection by circulating CA 125 in the context of anti-CA 125 autoantibody levels: Results from the EPIC cohort","volume":"142","author":"Fortner","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12032-017-1026-y","article-title":"Ovarian cancer recurrence and early detection: May HE4 play a key role in this open challenge? A systematic review of literature","volume":"34","author":"Capriglione","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/14737140.2017.1360138","article-title":"The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: A systematic review","volume":"17","author":"Scaletta","year":"2017","journal-title":"Expert Rev. Anticancer. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","article-title":"HE4: A new potential early biomarker for the recurrence of ovarian cancer","volume":"31","author":"Anastasi","year":"2010","journal-title":"Tumor Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1515\/cclm-2011-0477","article-title":"Diagnostic value of HE4 for ovarian cancer: A meta-analysis","volume":"50","author":"Yu","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1097\/IGC.0000000000000944","article-title":"The role of HE4, a novel biomarker, in predicting optimal cytoreduction after neoadjuvant chemotherapy in advanced ovarian cancer","volume":"27","author":"Plotti","year":"2017","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1080\/14737159.2017.1326820","article-title":"The role of biomarkers in the management of epithelial ovarian cancer","volume":"17","author":"Yang","year":"2017","journal-title":"Expert Rev. Mol. Diagn."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.gore.2018.07.002","article-title":"Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam","volume":"25","author":"Huy","year":"2018","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/AOG.0b013e318224fce2","article-title":"Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass","volume":"118","author":"Moore","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"82.e1","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"Coleman","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"298","DOI":"10.15430\/JCP.2013.18.4.298","article-title":"Ovarian cancer biomarker discovery based on genomic approaches","volume":"18","author":"Lee","year":"2013","journal-title":"J. Cancer Prev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","article-title":"Homologous recombination deficiency and ovarian cancer","volume":"60","author":"Ledermann","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ. Mol. Mutagen."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/cr.2008.1","article-title":"Homologous recombination in DNA repair and DNA damage tolerance","volume":"18","author":"Li","year":"2008","journal-title":"Cell Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.1093\/nar\/gks270","article-title":"Homologous recombination and its regulation","volume":"40","author":"Krejci","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"5584","DOI":"10.1038\/s41467-020-19406-4","article-title":"Pan-cancer landscape of homologous recombination deficiency","volume":"11","author":"Nguyen","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3892\/or.2013.2541","article-title":"Hereditary breast and ovarian cancer susceptibility genes (Review)","volume":"30","author":"Kobayashi","year":"2013","journal-title":"Oncol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","article-title":"PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance","volume":"8","author":"Rose","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1615\/CritRevEukaryotGeneExpr.2013006875","article-title":"Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases","volume":"24","author":"Morales","year":"2014","journal-title":"Crit. Rev. Eukaryot. Gene Expr."},{"key":"ref_33","first-page":"215","article-title":"PARP inhibitors: Review of mechanisms of action and BRCA1\/2 mutation targeting","volume":"15","author":"Dziadkowiec","year":"2016","journal-title":"Przegl\u0105d Menopauzalny"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e46263","DOI":"10.15252\/embr.201846263","article-title":"Mechanisms for stalled replication fork stabilization: New targets for synthetic lethality strategies in cancer treatments","volume":"19","author":"Liao","year":"2018","journal-title":"EMBO Rep."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S0090-8258(22)01414-7","article-title":"Correlation of BRCA and HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer in the age of PARPi maintenance therapy (187)","volume":"166","author":"Sims","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/1541-7786.MCR-18-0034","article-title":"Biomarker Assessment of HR Deficiency, Tumor BRCA1\/2 Mutations, and CCNE1 Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy","volume":"16","author":"Stronach","year":"2018","journal-title":"Mol. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"100144","DOI":"10.1016\/j.esmoop.2021.100144","article-title":"The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: Do we need it?","volume":"6","author":"Ngoi","year":"2021","journal-title":"ESMO Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.annonc.2020.08.2102","article-title":"ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer","volume":"31","author":"Miller","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s007950300002","article-title":"Histological classification of ovarian cancer","volume":"36","author":"Kaku","year":"2003","journal-title":"Med. Electron Microsc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.humpath.2011.03.003","article-title":"Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer\u2014Shifting the paradigm","volume":"42","author":"Kurman","year":"2011","journal-title":"Hum. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.ajpath.2020.09.006","article-title":"The Origin of Ovarian Cancer Species and Precancerous Landscape","volume":"191","author":"Shih","year":"2021","journal-title":"Am. J. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1158\/0008-5472.CAN-11-3911","article-title":"The changing view of high-grade serous ovarian cancer","volume":"72","author":"Berns","year":"2012","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"6618","DOI":"10.1158\/1078-0432.CCR-14-1292","article-title":"Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver","volume":"20","author":"Emmanuel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_44","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: An overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/path.5545","article-title":"Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities","volume":"253","author":"Cheasley","year":"2021","journal-title":"J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ygyno.2015.12.018","article-title":"Wilms tumor protein 1 (WT1)-- not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma","volume":"140","author":"Taube","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/00004347-200404000-00004","article-title":"WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium","volume":"23","author":"Acs","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1080\/00313020802320697","article-title":"WT1 expression in endometrioid ovarian carcinoma with and without associated endometriosis","volume":"40","author":"Stewart","year":"2008","journal-title":"Pathology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/apm.12784","article-title":"Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma","volume":"126","author":"Rekhi","year":"2018","journal-title":"Apmis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis","volume":"2","author":"Rivlin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/his.12349","article-title":"Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry","volume":"64","author":"Kobel","year":"2014","journal-title":"Histopathology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"15818","DOI":"10.18632\/oncotarget.24530","article-title":"WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas and their relation to prognosis","volume":"9","author":"Sallum","year":"2018","journal-title":"Oncotarget"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.humpath.2018.10.020","article-title":"Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: An investigation of the Tumor Bank Ovarian Cancer Network","volume":"85","author":"Sehouli","year":"2019","journal-title":"Hum. Pathol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2019.11.029","article-title":"Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma","volume":"157","author":"Fernandez","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2217\/bmm-2018-0311","article-title":"IGF1R predicts better survival in high-grade serous epithelial ovarian cancer patients and correlates with hCtr1 levels","volume":"13","author":"Deo","year":"2019","journal-title":"Biomark. Med."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ctrv.2017.08.012","article-title":"IGF system targeted therapy: Therapeutic opportunities for ovarian cancer","volume":"60","author":"Meijering","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/path.3035","article-title":"Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer","volume":"226","author":"Furlong","year":"2012","journal-title":"J. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ygyno.2014.03.557","article-title":"Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer","volume":"133","author":"Alkema","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_59","first-page":"2254","article-title":"Prostaglandin D2 expression is prognostic in high-grade serous ovarian cancer","volume":"41","author":"Alves","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1349-7006.2008.00747.x","article-title":"Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma","volume":"99","author":"Itamochi","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/PGP.0b013e318273fd07","article-title":"HNF-1beta in ovarian carcinomas with serous and clear cell change","volume":"32","author":"DeLair","year":"2013","journal-title":"Int. J. Gynecol. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.humpath.2006.12.018","article-title":"Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endometrium","volume":"38","author":"Yamamoto","year":"2007","journal-title":"Hum. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/modpathol.2014.61","article-title":"Napsin A is a specific marker for ovarian clear cell adenocarcinoma","volume":"28","author":"Yamashita","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4611","DOI":"10.1038\/s41388-018-0300-6","article-title":"ARID1A mutation sensitizes most ovarian clear cell carcinomas to BET inhibitors","volume":"37","author":"Berns","year":"2018","journal-title":"Oncogene"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/modpathol.2013.216","article-title":"Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations and ZNF217 amplification in ovarian clear cell carcinoma","volume":"27","author":"Huang","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cjp2.103","article-title":"Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers","volume":"4","author":"Khalique","year":"2018","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Zhu, C., Zhu, J., Qian, L., Liu, H., Shen, Z., Wu, D., Zhao, W., Xiao, W., and Zhou, Y. (2021). Clinical characteristics and prognosis of ovarian clear cell carcinoma: A 10-year retrospective study. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08061-7"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/modpathol.2009.40","article-title":"Glypican-3 expression in clear cell adenocarcinoma of the ovary","volume":"22","author":"Maeda","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/dc.20623","article-title":"Immunocytochemistry for hepatocyte nuclear factor-1beta (HNF-1beta): A marker for ovarian clear cell carcinoma","volume":"35","author":"Kato","year":"2007","journal-title":"Diagn. Cytopathol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1111\/IGC.0b013e3181a83f1d","article-title":"HOXA10 is overexpressed in human ovarian clear cell adenocarcinoma and correlates with poor survival","volume":"19","author":"Li","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sato, E., Nakayama, K., Razia, S., Nakamura, K., Ishikawa, M., Minamoto, T., Ishibashi, T., Yamashita, H., Iida, K., and Kyo, S. (2018). ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19061710"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ygyno.2019.12.015","article-title":"Therapeutic options for mucinous ovarian carcinoma","volume":"156","author":"Gorringe","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Chay, W.Y., Chew, S.H., Ong, W.S., Busmanis, I., Li, X., Thung, S., Ngo, L., Lim, S.L., Lim, Y.K., and Chia, Y.N. (2013). HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0061565"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ygyno.2021.10.078","article-title":"Clinical factors and biomarker profiles associated with patient outcome in endometrioid ovarian carcinoma\u2014Emphasis on tumor grade","volume":"164","author":"Soovares","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"420","DOI":"10.21037\/tlcr.2016.08.06","article-title":"Pros: Can tissue biopsy be replaced by liquid biopsy?","volume":"5","author":"Hofman","year":"2016","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13046-020-01601-2","article-title":"Liquid biopsy and tumor heterogeneity in metastatic solid tumors: The potentiality of blood samples","volume":"39","author":"Russano","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_77","first-page":"4111","article-title":"Current methodologies to detect circulating tumor cells: A focus on ovarian cancer","volume":"11","author":"Lemma","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"10939","DOI":"10.2147\/CMAR.S211455","article-title":"Circulating Tumor Cell Detection In Epithelial Ovarian Cancer Using Dual-Component Antibodies Targeting EpCAM And FR\u03b1","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"48820","DOI":"10.18632\/oncotarget.16179","article-title":"EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy","volume":"8","author":"Chebouti","year":"2017","journal-title":"Oncotarget"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1515\/cclm-2017-0019","article-title":"Liquid biopsy in ovarian cancer: Recent advances on circulating tumor cells and circulating tumor DNA","volume":"56","author":"Giannopoulou","year":"2018","journal-title":"Clin. Chem. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13048-017-0369-5","article-title":"Circulating cell-free DNA and circulating tumor cells, the \u201cliquid biopsies\u201d in ovarian cancer","volume":"10","author":"Cheng","year":"2017","journal-title":"J. Ovarian Res."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13073-017-0500-7","article-title":"The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer","volume":"9","author":"Widschwendter","year":"2017","journal-title":"Genome Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"182","DOI":"10.3389\/fcell.2019.00182","article-title":"Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives","volume":"7","author":"Singh","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Xi, X., Li, T., Huang, Y., Sun, J., Zhu, Y., Yang, Y., and Lu, Z.J. (2017). RNA Biomarkers: Frontier of Precision Medicine for Cancer. Noncoding RNA, 3.","DOI":"10.3390\/ncrna3010009"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Ning, L., Lang, J., and Wu, L. (2022). Plasma circN4BP2L2 is a promising novel diagnostic biomarker for epithelial ovarian cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-021-09073-z"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"9715","DOI":"10.2147\/OTT.S211413","article-title":"Utility Of Plasma circBNC2 As A Diagnostic Biomarker In Epithelial Ovarian Cancer","volume":"12","author":"Hu","year":"2019","journal-title":"Onco Targets"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"7451","DOI":"10.2147\/OTT.S220700","article-title":"Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer","volume":"12","author":"Wang","year":"2019","journal-title":"Onco Targets"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41420-022-00825-9","article-title":"Long non-coding RNA SNHG10 upregulates BIN1 to suppress the tumorigenesis and epithelial\u2013mesenchymal transition of epithelial ovarian cancer via sponging miR-200a-3p","volume":"8","author":"Lv","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Zalfa, F., Perrone, M.G., Ferorelli, S., Laera, L., Pierri, C.L., Tolomeo, A., Dimiccoli, V., Perrone, G., De Grassi, A., and Scilimati, A. (2022). Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma. Cancers, 14.","DOI":"10.3390\/cancers14153764"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00404-021-06138-z","article-title":"New biomarkers in peripheral blood of patients with ovarian cancer: High expression levels of miR-16-5p, miR-17-5p, and miR-638","volume":"305","author":"Saral","year":"2022","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1021\/acsbiomaterials.1c00217","article-title":"Potential Use of Exosomes as Diagnostic Biomarkers and in Targeted Drug Delivery: Progress in Clinical and Preclinical Applications","volume":"7","author":"Huda","year":"2021","journal-title":"ACS Biomater. Sci. Eng."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"9801","DOI":"10.1007\/s11033-020-05993-4","article-title":"Endosomes, lysosomes, and the role of endosomal and lysosomal biogenesis in cancer development","volume":"47","author":"Jeger","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ygyno.2008.04.033","article-title":"MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer","volume":"110","author":"Taylor","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","article-title":"Exosome-based liquid biopsies in cancer: Opportunities and challenges","volume":"32","author":"Yu","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1002\/1878-0261.12371","article-title":"Exosomal microRNAs as tumor markers in epithelial ovarian cancer","volume":"12","author":"Pan","year":"2018","journal-title":"Mol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Horie, K., Nanashima, N., Yokoyama, Y., Yoshioka, H., and Watanabe, J. (2022). Exosomal MicroRNA as Biomarkers for Diagnosing or Monitoring the Progression of Ovarian Clear Cell Carcinoma: A Pilot Study. Molecules, 27.","DOI":"10.3390\/molecules27123953"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ygyno.2017.11.005","article-title":"Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer","volume":"148","author":"Shah","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3390\/cimb44010021","article-title":"Circulating Exosomal miR-1290 for Diagnosis of Epithelial Ovarian Cancer","volume":"44","author":"Jeon","year":"2022","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"16606","DOI":"10.1074\/jbc.M111.227611","article-title":"miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein","volume":"286","author":"Dar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1530\/JME-15-0182","article-title":"Modulatory role of miR-205 in angiogenesis and progression of thyroid cancer","volume":"55","author":"Salajegheh","year":"2015","journal-title":"J. Mol. Endocrinol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/ncb1722","article-title":"The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1","volume":"10","author":"Gregory","year":"2008","journal-title":"Nat. Cell Biol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"18498","DOI":"10.18632\/aging.203298","article-title":"Exosomal miRNA-205 promotes breast cancer chemoresistance and tumorigenesis through E2F1","volume":"13","author":"Zhao","year":"2021","journal-title":"Aging"},{"key":"ref_103","first-page":"1719","article-title":"Proteomics profiling of plasma exosomes in epithelial ovarian cancer: A potential role in the coagulation cascade, diagnosis and prognosis","volume":"54","author":"Zhang","year":"2019","journal-title":"Int. J. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2478\/raon-2019-0003","article-title":"Potential of osteopontin in the management of epithelial ovarian cancer","volume":"53","author":"Cerne","year":"2019","journal-title":"Radiol. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10689-015-9847-3","article-title":"Diagnostic values of osteopontin combined with CA125 for ovarian cancer: A meta-analysis","volume":"15","author":"Lan","year":"2015","journal-title":"Fam. Cancer"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yexcr.2017.10.018","article-title":"Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells\u2014An updated review","volume":"362","author":"Muinao","year":"2018","journal-title":"Exp. Cell Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12014-017-9169-6","article-title":"A multiplex platform for the identification of ovarian cancer biomarkers","volume":"14","author":"Boylan","year":"2017","journal-title":"Clin. Proteom."},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Wanyama, F.M., and Blanchard, V. (2021). Glycomic-Based Biomarkers for Ovarian Cancer: Advances and Challenges. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040643"},{"key":"ref_109","first-page":"299","article-title":"Copper isotope effect in serum of cancer patients. A pilot study","volume":"7","author":"Puisieux","year":"2014","journal-title":"Metallomics"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Leli\u00e8vre, P., Sancey, L., Coll, J.L., Deniaud, A., and Busser, B. (2020). The Multifaceted Roles of Copper in Cancer: A Trace Metal Element with Dysregulated Metabolism, but Also a Target or a Bullet for Therapy. Cancers, 12.","DOI":"10.20944\/preprints202010.0353.v1"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"126611","DOI":"10.1016\/j.jtemb.2020.126611","article-title":"Cu isotope ratios are meaningful in ovarian cancer diagnosis","volume":"62","author":"Toubhans","year":"2020","journal-title":"J. Trace Elem. Med. Biol."},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Wu, D., Rice, C.M., and Wang, X. (2012). Cancer bioinformatics: A new approach to systems clinical medicine. BMC Bioinform., 13.","DOI":"10.1186\/1471-2105-13-71"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/nar\/30.1.207","article-title":"Gene Expression Omnibus: NCBI gene expression and hybridization array data repository","volume":"30","author":"Edgar","year":"2002","journal-title":"Nucleic Acids Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nrc1214","article-title":"Analysing differential gene expression in cancer","volume":"3","author":"Liang","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3389\/fgene.2019.01031","article-title":"Identification of Potential Biomarkers in Association With Progression and Prognosis in Epithelial Ovarian Cancer by Integrated Bioinformatics Analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13048-019-0575-4","article-title":"Increased expression of TET3 predicts unfavorable prognosis in patients with ovarian cancer-a bioinformatics integrative analysis","volume":"12","author":"Cao","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"11023","DOI":"10.1002\/jcp.27926","article-title":"Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments","volume":"234","author":"Zheng","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12935-022-02566-2","article-title":"PTH2R is related to cell proliferation and migration in ovarian cancer: A multi-omics analysis of bioinformatics and experiments","volume":"22","author":"Xiaowei","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Liu, H., Chen, C., Fehm, T., Cheng, Z., and Neubauer, H. (2022). Identifying Mitotic Kinesins as Potential Prognostic Biomarkers in Ovarian Cancer Using Bioinformatic Analyses. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020470"},{"key":"ref_120","first-page":"5113447","article-title":"Integrated Bioinformatics Analysis for Identification of the Hub Genes Linked with Prognosis of Ovarian Cancer Patients","volume":"2022","author":"Li","year":"2022","journal-title":"Comput. Math. Methods Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ncponc0176","article-title":"Bioinformatics in cancer therapeutics\u2014Hype or hope?","volume":"2","author":"Simon","year":"2005","journal-title":"Nat. Clin. Pract. Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/713\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:34:38Z","timestamp":1760121278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/13\/4\/713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":121,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["diagnostics13040713"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics13040713","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]}}}